PLX-R18 has shown potential promise in significantly improving survival and accelerating recovery from H-ARS in preclinical animal and human studies, conducted with support from leading global health ...
The FDA has approved the therapy for 14 conditions, ranging from severe gangrene to certain infections, burns, radiation injury, and crush injuries. Of these conditions, the two that perhaps best show ...